An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512136-30-00

Enrollment

175

Registered

2024-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma multiforme

Brief summary

1. Immunological changes in patients during the course of the disease before and under bevacizumab treatment, which might predict the course of the disease. 2. Local relapse free survival 3. Progression free survival 4. Overall survival.

Detailed description

Investigation of plasma-derived extracellular vesicles (EV), their micro-RNA and protein content, and free DNA-RNA fragments. We do not perform genome sequencing.

Interventions

DRUGBEVACIZUMAB

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Immunological changes in patients during the course of the disease before and under bevacizumab treatment, which might predict the course of the disease. 2. Local relapse free survival 3. Progression free survival 4. Overall survival.	—

Secondary

Measure	Time frame
Investigation of plasma-derived extracellular vesicles (EV), their micro-RNA and protein content, and free DNA-RNA fragments. We do not perform genome sequencing.	—

Countries

Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026